Tag: Car-T

Treating the Untreatable with Precision Therapies – A $4 trillion Opportunity?

Precision Therapies For Targeted Results Precision therapies have always been the ultimate goal of medicine. Instead of drugs acting on multiple parts of the body, these therapies would only target one organ, one cell, or even one gene. In theory, not only would this be a lot more efficient, but…

Continue Reading Treating the Untreatable with Precision Therapies – A $4 trillion Opportunity?

what will therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a declining cancer death rate – by 33% to be precise – since the…

Continue Reading what will therapy look like in 2034?

Unveiling tomorrow’s cures: insights from Cardinal Health

This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health.  The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and Advanced Therapies Week. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals…

Continue Reading Unveiling tomorrow’s cures: insights from Cardinal Health

Implementing Bispecific Treatments

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA. In this segment, Mahmoudjafari and Mancini discuss the implementation of step-up dosing for bispecific therapies in lymphoma patients. Mancini details the multifaceted approach at his…

Continue Reading Implementing Bispecific Treatments

Ten NK cell therapy companies to look out for this year

Natural killer (NK) cells are white blood cells that are a part of the body’s defense mechanism. These cells are on the lookout for any kind of disruption in the immune system, and can kill diseased cells like tumor cells. NK cells are being used in clinical applications to treat…

Continue Reading Ten NK cell therapy companies to look out for this year

Could natural killer cells revolutionize Alzheimer’s treatment?

This week on the podcast, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s disease treatment landscape with natural killer cells. The company’s natural killer (NK) cell Alzheimer’s treatment uses a patient’s cells, collected by a simple…

Continue Reading Could natural killer cells revolutionize Alzheimer’s treatment?

Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma

Lisocabtagene maraleucel (liso-cel; Breyanzi®; Bristol-Myers Squibb), a CD19-directed genetically modified autologous T-cell immunotherapy, also known as chimeric antigen receptor (CAR) T-cell therapy, is a cost effective second line treatment for relapsed and refractory diffuse large B-cell lymphoma (r/r DLBCL). This conclusion is based on results from a study published in…

Continue Reading Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma

How MRD Testing Can Help

MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…

Continue Reading How MRD Testing Can Help

[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]

Objective: To explore the prognostic value of circulating tumor DNA (ctDNA) testing in patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy, and to guide the prevention and subsequent treatment of CAR-T-cell therapy failure. Methods: In this study, 48 patients with R/R DLBCL…

Continue Reading [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]

Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell Lymphoma From ASH 2023

1. FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. News release. US Food and Drug Administration. June 21, 2023. Accessed December 6, 2023. www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b 2. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell…

Continue Reading Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell Lymphoma From ASH 2023

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Big problems, small solutions: how synthetic biology is building a stronger future

Damaris Mills is its president Integrated DNA TechnologiesA global genomics solutions provider. getty Every fall, millions of Americans get their annual flu shots — and while they’re at it, they now also get their annual Covid-19 booster. Already, these shots seem routine; It’s easy to forget that the initial COVID-19…

Continue Reading Big problems, small solutions: how synthetic biology is building a stronger future

ASH 2023: Lymphoma Studies May Inform Practice

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Continue Reading ASH 2023: Lymphoma Studies May Inform Practice

How Synthetic Biology Is Building A Stronger Future

Demaris Mills is president at Integrated DNA Technologies, a global genomics solutions provider. getty Every fall, millions of Americans get their annual flu shots—and while they are at it, they now also get their annual Covid-19 boosters. Already, these shots seem routine; it is easy to forget that the initial…

Continue Reading How Synthetic Biology Is Building A Stronger Future

Nine biotech companies to watch in 2024

As 2024 unfolds, the biotechnology industry is brimming with potential, spearheading scientific innovation. This year is particularly exciting as a diverse range of biotech companies are poised to break new ground to tackle global challenges. Here are nine biotech companies we will follow in 2024. Aiolos Bio Aiolos Bio has…

Continue Reading Nine biotech companies to watch in 2024

Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. {Delhi, India} To…

Continue Reading Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone —…

Continue Reading Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Brace yourselves for these trends in clinical research in 2024

There’s an air of cautious optimism about 2024, after a difficult few years following the end of the pandemic when investment in pharma and biotech research dropped substantially. After this significant reset, there’s now hope that in 2024, in line with emerging trends, the funds will be there for the…

Continue Reading Brace yourselves for these trends in clinical research in 2024

CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

(MENAFN– The Express Wire) The Global “CAR-T Cell Immunotherapies for Cancer Market ” Growth Forecast Report 20242031 is an essential tool for understanding the growth strategies, and various segments of industry by Type [ CD19, BCMA, EPCAM ] and Applications [ Hematological Cancer, Solid Tumor, Other Oncological Disorders ]. The…

Continue Reading CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. Article  CAS  PubMed  Google Scholar  Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie…

Continue Reading Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Precision Medicine: A New Era in Cancer Therapy

Precision medicine can offer improved clinical outcomes by assessing the unique characteristics of tumors, such as their likelihood of developing resistance to chemotherapy. Stay up to date on the latest science with Brush Up Summaries.  Precision Medicine in Cancer Precision medicine for cancer treatment involves tailoring treatments to an individual…

Continue Reading Precision Medicine: A New Era in Cancer Therapy

$51 Million Raised To Develop New Class Of Immune Evasive iPS-T Cell Therapies

Shinobi Therapeutics – a biotechnology company developing a new class of immune evasive iPS-T cell therapies – recently announced that it has closed a $51 million Series A financing. The oversubscribed funding round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with participation from Astellas…

Continue Reading $51 Million Raised To Develop New Class Of Immune Evasive iPS-T Cell Therapies

Feeder-cell alternatives for large-cell iPSC manufacturing

Cellular immunotherapy—for example, Chimeric Antigen Receptor (CAR)-T cell therapy—has shown great efficacy in treating various hematologic malignancies. CAR-T therapy has undergone notable changes, and several drugs have received regulatory approval for commercial use. Despite these achievements, substantial challenges remain in the widespread use of autologous CAR-T therapy, such as the…

Continue Reading Feeder-cell alternatives for large-cell iPSC manufacturing

Zafrens Plans to Advance Multimodal Drug Discovery Platform with $23M Financing

Although he started out in theoretical physics, Swamy Vijayan, PhD, has worked in the biotechnology industry for most of his professional career. His path included a stint at Illumina and the launch of Omniome, a short read sequencing company that was acquired by Pacific Biosciences in 2021. His next gig…

Continue Reading Zafrens Plans to Advance Multimodal Drug Discovery Platform with $23M Financing

Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL

T-cell engaging therapeutic approaches have significantly changed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in recent years. “They are, by a wide margin, the most impactful new therapies for all B-cell lymphomas, but especially DLBCL, in the last 40 years, if not ever,” said Joshua…

Continue Reading Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL

Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL

Date of Abstract presentation 10th December 2023 Indications Diffuse Large B-cell lymphoma (DLBCL) Abstract Number 436 Abstract type Oral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The primary analysis of the…

Continue Reading Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL

3 Biotechs With Promising Gene Therapies in the Spotlight

Recently, bluebird bio, Inc. BLUE obtained FDA approval for its third gene therapy, lovotibeglogene autotemcel (lovo-cel), for the treatment of sickle cell disease (“SCD”) in patients aged 12 and older who have a history of vaso-occlusive events (“VOEs”). The FDA approved lovo-cel under the brand name Lyfgenia. Concurrently, it also…

Continue Reading 3 Biotechs With Promising Gene Therapies in the Spotlight

a beacon of hope in glioblastoma treatment

Glioblastoma is an extremely aggressive type of brain cancer and is the most common type of primary malignant brain tumor in adults. There is currently no cure for it and, due to its fast-growing nature and location, it is very difficult to treat. But could CAR-T cell therapy – which…

Continue Reading a beacon of hope in glioblastoma treatment

Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair

Khan, S. et al. Role of recombinant DNA technology to improve life. Int. J. Genomics Proteomics 2016, 2405954 (2016). Google Scholar  Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018). Article  CAS  PubMed  Google…

Continue Reading Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair

Complete Interim Response, SCT Beats CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Complete Interim Response, SCT Beats CAR T

CRS Occurs in More Than Half of CAR-T Therapy Recipients

Real-world data suggested that cytokine release syndrome (CRS) among chimeric antigen receptor (CAR) T-cell therapy recipients with hematologic malignancy occurred among 56.2% to 71.7% of patients, according to results of a study that were presented at the ASH Annual Meeting 2023. “CRS is a potentially life threatening and supraphysiological response…

Continue Reading CRS Occurs in More Than Half of CAR-T Therapy Recipients

Multicenter Study at Sylvester, Other Academic Centers Shows CAR-T Cell Therapy Safe, Effective Even for High-Risk Patients

“CAR-T has caused a paradigm shift in the treatment of patients with diffuse large B-cell lymphoma,” said Jay Y. Spiegel, MD, hematologist-oncologist at Sylvester Comprehensive Cancer Center and the study’s lead presenter at ASH. “Our findings support the vast potential of this therapy, even for high-risk patients, but highlight the…

Continue Reading Multicenter Study at Sylvester, Other Academic Centers Shows CAR-T Cell Therapy Safe, Effective Even for High-Risk Patients

NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

NX-1607 in DLBCL | Image Credit: © freshidea – stock.adobe.com The phase 1a/1b NX-1607-101 trial (NCT05107674) will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma (DLBCL), according to a poster that was presented during the 2023 ASH Annual Meeting. The dose-escalation portion of…

Continue Reading NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting | Vaccines

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Details Category: Vaccines Published on Tuesday, 12 December 2023 14:30 Hits: 227 Positive preliminary efficacy data with a favorable safety profile support…

Continue Reading Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting | Vaccines

CAR-T Cell Therapy Revolutionizes DLBCL Treatment

Groundbreaking advancements in the field of medical science have given rise to a new era in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). One such major development is the introduction of chimeric antigen receptor T (CAR-T) cell therapy, a form of immunotherapy that has shown promising results in treating…

Continue Reading CAR-T Cell Therapy Revolutionizes DLBCL Treatment

Recent Developments in Lymphoma Treatment

Combination Therapy Shows Promising Results In a recent Phase 1/2 trial, a combination of mosunetuzumab, a CD20-CD3 bispecific antibody, and polatuzumab vedotin, an anti-CD79B antibody-drug conjugate, demonstrated a significant overall response rate of 59.2% in patients with relapsed or refractory large B Cell lymphoma. This study, presented at the ASH23…

Continue Reading Recent Developments in Lymphoma Treatment

Comprehensive Review of Small Interfering RNAs (siRNAs)

Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…

Continue Reading Comprehensive Review of Small Interfering RNAs (siRNAs)

The future of cancer care: a path toward personalized treatment

The biological complexity of cancer is individual to each patient, and it presents many roadblocks on the path toward optimal treatments. However, developments in DNA technologies and advanced imaging tools have greatly informed clinicians and researchers on ways to develop methods for precision care. Morgridge biomedical imaging investigator Dr. Melissa Skala and…

Continue Reading The future of cancer care: a path toward personalized treatment

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Caribou Biosciences, Inc. — Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2…

Continue Reading Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

ADC Therapeutics Announces Initial Results from

Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with…

Continue Reading ADC Therapeutics Announces Initial Results from

CAR-T Cell Therapy is Safe, Effective in DLBCL, Including High-Risk Patients

Study results demonstrate that CAR-T cell therapy—a type of immunotherapy that genetically reengineers T cells to help the immune system find and kill cancerous cells—is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL). In addition, this therapy was found safe in patients who are considered high risk…

Continue Reading CAR-T Cell Therapy is Safe, Effective in DLBCL, Including High-Risk Patients

Caribou Biosciences Provides Regulatory Update on CB-010

— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — —…

Continue Reading Caribou Biosciences Provides Regulatory Update on CB-010

Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

Credit: Pixabay/CC0 Public Domain CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities. That’s the conclusion of a five-year analysis of results from the U.S. Lymphoma CAR-T Cell Consortium, a group of 17 academic…

Continue Reading Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

Proceeds to support company in advancing its first off-the-shelf iPS-T cell therapy against GPC3+ cancers toward the clinic Oversubscribed Series A led by EQT Life Sciences, F-Prime Capital and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative (FTI), JIC Venture Growth Investments, and D3 LLC…

Continue Reading Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

Integrating CAR-T cell therapy into the management of DLBCL: what we are learning

Introduction: Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The weakness of CAR-T therapies is that there are no comparative clinical trials, although many publications based on real-life data have confirmed the results…

Continue Reading Integrating CAR-T cell therapy into the management of DLBCL: what we are learning

Regeneron announces new, updated data for odronextamabn in R/R DLBCL

Regeneron Pharmaceuticals announced new and updated data for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, or DLBCL. The data from the pivotal Phase 2 trial and Phase 1 trial were shared in several presentations – including two orals – at the 65th American Society of Hematology Annual Meeting…

Continue Reading Regeneron announces new, updated data for odronextamabn in R/R DLBCL

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes | Antibodies

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes Details Category: Antibodies Published on Monday, 11 December 2023 10:18 Hits: 243 Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration…

Continue Reading Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes | Antibodies

Regeneron Presents Positive Phase II Results for its Lymphoma Drug

Pictured: Regeneron logo on a light brown building/Shutterstock, Lev Radin Regeneron has lifted the curtain on Phase II data for odronextamab, which it is investigating in patients with relapsed/refractory follicular lymphoma. Regeneron’s investigational CD20xCD3 bispecific antibody results were announced Sunday at the American Society of Hematology annual meeting. Regeneron said…

Continue Reading Regeneron Presents Positive Phase II Results for its Lymphoma Drug

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting

This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Breadcrumb Trail Links PMN Press Releases Business Wire News Releases Author of the…

Continue Reading City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting

Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So

Just a few years ago, chimeric antigen receptor (CAR) T-cell therapy was brand new, offering a novel solution for populations of patients who were short on options and typically faced grim prognoses. But this weekend at the American Society of Hematology Annual Meeting and Exposition, a presentation saw experts in…

Continue Reading Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So

Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…

Continue Reading Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL

Cyrus M. Khan, MD (MODERATOR) Hematologist Division of Hematology and Cellular Therapy West Penn Hospital of Allegheny Health Network Pittsburgh, PA EVENT REGION Pennsylvania PARTICIPANT LIST Haixia Qin, MD, PhD | Simi Rai, MD | Naeem Latif, MD | Alexander Barsouk, MD | Gurprataap Sanhu, MD | Hayman Salib, MD…

Continue Reading Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL

Updated Odronextamab Data from Relapsed/Refractory Diffuse

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…

Continue Reading Updated Odronextamab Data from Relapsed/Refractory Diffuse

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need for new treatments for peripheral T cell lymphoma (PTCL) Results confirmed patient eligibility requirements and endpoints planned for soquelitinib Phase 3 clinical…

Continue Reading Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals Presents New Interim Soquelitinib

Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need for new treatments for peripheral T cell lymphoma (PTCL) Results confirmed patient eligibility requirements and endpoints planned for soquelitinib Phase 3 clinical…

Continue Reading Corvus Pharmaceuticals Presents New Interim Soquelitinib

Seattle Hub for Synthetic Biology aims to turn cells into recorders

Jay Shendure, a professor of genome sciences at UW Medicine, will be executive director of the Seattle Hub for Synthetic Biology. (UW Medicine Photo) The Allen Institute, the Chan Zuckerberg Initiative and the University of Washington have launched a collaboration called the Seattle Hub for Synthetic Biology, with the goal…

Continue Reading Seattle Hub for Synthetic Biology aims to turn cells into recorders

Future-focused therapeutics | Scientist Live

Base editing is bringing the next breakthrough in cell and gene therapy, explains Michelle Fraser. Cell and gene therapies (CGTs) hold the promise to transform medicine for patients globally. These therapies work by correcting DNA to treat a genetic disease, or by modifying cells from the immune system to specifically…

Continue Reading Future-focused therapeutics | Scientist Live

CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL

By The ASCO Post StaffPosted: 12/6/2023 9:39:00 AM Last Updated: 12/6/2023 10:33:56 AM Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al…

Continue Reading CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL

CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum

NANJING, China, Dec. 7, 2023 /PRNewswire/ — The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagination. Particularly in the field of cellular gene therapy, a series of recent positive developments have been overwhelming. Recently, the world’s first CRISPR/Cas9…

Continue Reading CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum

Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Market Overview and Report Coverage Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that primarily affects the lymph nodes and skin. It is characterized by the abnormal growth of large cells called anaplastic lymphoma kinase (ALK)-positive or ALK-negative lymphoma cells. The ALCL therapeutics market pertains to…

Continue Reading Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Cost-Effectiveness and Health Care Spending

Chimeric antigen receptor T-cell (CAR-T) therapies, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), have been hailed as breakthroughs in the treatment of various cancers. However, a recent study published in the Annals of Internal Medicine has raised questions about their cost-effectiveness for patients with diffuse large B-cell lymphoma…

Continue Reading Cost-Effectiveness and Health Care Spending

FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia

An investigational new drug application was cleared by the FDA for CT071 in this indication. CT071 is an autologous chimeric antigen receptor (CAR) T-cell therapy candidate being developed for the treatment of multiple myeloma (MM) and primary plasma cell leukemia (PCL). A phase 1 trial evaluating CT071 is ongoing in…

Continue Reading FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

CRISPR Therapeutics CRSP announced new updates on its immuno-oncology pipeline, focused on developing CRISPR/Cas9 gene-edited allogeneic CAR T cell product candidates. CRSP announced its decision to discontinue the development of first-generation allogeneic CAR T product candidates, CTX110 (targeting CD19) and CTX130 (targeting CD70). Management will focus on developing their respective…

Continue Reading CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline – December 5, 2023

CRISPR Therapeutics (CRSP Quick QuoteCRSP – Free Report) announced new updates on its immuno-oncology pipeline, focused on developing CRISPR/Cas9 gene-edited allogeneic CAR T cell product candidates. CRSP announced its decision to discontinue the development of first-generation allogeneic CAR T product candidates, CTX110 (targeting CD19) and CTX130 (targeting CD70). Management will…

Continue Reading CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline – December 5, 2023

Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM

Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Attend In-Person or Virtually for an exciting and informative event, Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care, happening at the San Diego Convention Center on Friday, December 8, 2023, 3:00…

Continue Reading Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM

CRISPR Therapeutics’ Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases – CRISPR Therapeutics (NASDAQ:CRSP)

Monday, CRISPR Therapeutics AG CRSP provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates. The company’s first-generation allogeneic CAR T candidates, CTX110 and CTX130, provided important proof of concept that allogeneic CAR T cells can produce durable remissions following a standard lymphodepletion regimen. …

Continue Reading CRISPR Therapeutics’ Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases – CRISPR Therapeutics (NASDAQ:CRSP)

Study Finds Axicabtagene Ciloleucel and Lisocabtagene Maraleucel Not Cost-Effective

MONDAY, Dec. 4, 2023 (HealthDay News) — For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine. Amar H. Kelkar, M.D.,…

Continue Reading Study Finds Axicabtagene Ciloleucel and Lisocabtagene Maraleucel Not Cost-Effective

Wall Street eyes CRISPR Therapeutics’ growth By Investing.com

© Reuters. Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This Cyber Monday, enjoy up to 60% off, plus…

Continue Reading Wall Street eyes CRISPR Therapeutics’ growth By Investing.com

Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…

Continue Reading Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

What does it mean for oncology and beyond?

Chimeric antigen receptor (CAR) T-cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR T-cell…

Continue Reading What does it mean for oncology and beyond?

Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609(7926):354–60. Article  CAS  PubMed  PubMed Central  Google Scholar  Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2…

Continue Reading Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Ny tantaran’i Kim – DLBCL & CAR T-cell therapy

Tamin’ny Septambra 2020, i Kim dia voan’ny Lymphoma B-Cell Diffuse Large. Indrisy anefa fa tsy namaly ny fitsaboana tamin’ny voalohany i Kim. Ny ekipany ao amin’ny Hopitaly PA any Brisbane dia afaka nanondro azy ho any amin’ny ekipa mpitrandraka ao amin’ny RBWH mba hidirana amin’ny fitsaboana T-cell CAR vaovao. Hatramin’ny…

Continue Reading Ny tantaran’i Kim – DLBCL & CAR T-cell therapy

Whatha, FDA Warns Breakthrough Cancer Treatment Might Cause Cancer

In 2017, the U.S. Food and Drug Administration (FDA) approved a breakthrough treatment for blood cancer. But now, the agency cautions the treatment is not without risks and appears to have caused other cancers in a small number of patients. The FDA is investigating 19 new cases of cancer occurring…

Continue Reading Whatha, FDA Warns Breakthrough Cancer Treatment Might Cause Cancer

Physicians Consider Loncastuximab for Older Patients With R/R DLBCL

Paolo Strati, MD Assistant Professor Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, TX CASE SUMMARY: A 73-year-old woman presented with fever, headaches, and 7-lb unintentional weight loss​. She was married with 2 grown children who live in other states and the primary caretaker for her mother…

Continue Reading Physicians Consider Loncastuximab for Older Patients With R/R DLBCL

EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM-CAR-T cells for solid tumors. We demonstrated that EpCAM-CAR-T cells costimulated by Dectin-1 exhibited…

Continue Reading EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

The 6 Biggest Stories in Medicine in 2023

It’s so hard to avoid spoilers online. Take, for example, right now. Welcome back to our 7th edition of This Year in Medicine, our annual end-of-year recap series that highlights the greatest stories, challenges, moments and innovations in health care. On every Monday, Wednesday and Friday this December, our team…

Continue Reading The 6 Biggest Stories in Medicine in 2023

Gene Editing Market Size Worth USD 35.84 Billion in 2032 |

Vancouver, Nov. 30, 2023 (GLOBE NEWSWIRE) — The global gene editing market size was USD 6.11 Billion in 2021 and is expected to register a revenue CAGR of 17.5% during the forecast period. The global gene editing market is experiencing significant growth, driven by advancements in technology and a surge…

Continue Reading Gene Editing Market Size Worth USD 35.84 Billion in 2032 |

Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL

CASE A 67-year-old man presented with fatigue, back pain, and lymphadenopathy​. Medical history: Hypertension, well controlled with medication​ Physical exam: Left posterior cervical, 1.5-cm node; right anterior cervical node, 2.5-cm; left supraclavicular node, 2.0-cm​. PET-CT scan: multiple enlarged mesenteric and retroperitoneal nodes, largest measuring 5.3 x 3.1 cm​ Bone marrow biopsy was…

Continue Reading Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL

Postdoc Position in Bioinformatics/Computational biology

Job description A Bioinformatics/Computational biology postdoc position focusing on single or spatial proteogenomics is available in Dr. Chunchao Zhang laboratory at Children’s National Hospital and George Washington University School of Medicine and Health Sciences in Washington, DC. The majority of my research is geared towards interpretation and integration of different…

Continue Reading Postdoc Position in Bioinformatics/Computational biology

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte (eTIL) KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.1 The primary objective of the phase 1 portion of the…

Continue Reading FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

CRISPR Gene Editing: Cas9 and Beyond

Scientists use the CRISPR-Cas9 system to target a DNA sequence of interest near a protospacer-adjacent motif (PAM). The PAM initiates Cas9-DNA binding, a guide RNA (yellow) invades the double helix (blue) and hybridizes with the target DNA, and Cas9 (red) breaks the unwound double-stranded target DNA. iStock Meletios Verras Stay…

Continue Reading CRISPR Gene Editing: Cas9 and Beyond

Test our GMP media for your T and HEK cells

At Sartorius, we offer a wide range of high-quality media and critical raw materials. We help you find the best formulation for your processes by offering expert support for media and services. Our comprehensive services, along with this, can help you quickly commercialize your product. Find out more and request…

Continue Reading Test our GMP media for your T and HEK cells

CTLA4 Deletion Boosts CAR T-Cell Efficacy

Cancer Cell Image: © sipgus – stock.adobe.com CTLA4 deletion shows promise as a strategy to overcome T-cell dysfunction and may increase the efficacy of chimeric antigen receptor (CAR) T-cell therapy.1 According to findings published in Immunity, CTLA4 deletion in CAR T cells improves the antitumor efficacy and surface of CAR…

Continue Reading CTLA4 Deletion Boosts CAR T-Cell Efficacy

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article  CAS  PubMed  PubMed Central  Google Scholar  Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article  CAS  PubMed  Google Scholar  Lawrence…

Continue Reading Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

The Biotech Job Market: Navigating Challenges and Opportunities

The biotech industry has experienced significant ups and downs in recent years. While breakthroughs in CAR-T and CRISPR technologies have captivated the scientific community, the job market has taken a hit. According to recent data, the number of bioscience job postings has decreased from 19,000 in February 2022 to 10,000…

Continue Reading The Biotech Job Market: Navigating Challenges and Opportunities

MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

tonaquatic Thesis overview MorphoSys AG (NASDAQ:MOR) recently announced positive topline results from its phase 3 trial of pelabresib in myelofibrosis (MF). The study easily met the primary endpoint. However, despite the strong positive trend, statistical significance was not achieved at key secondary endpoints assessing symptomatic improvement. Nevertheless, in a pre-specified…

Continue Reading MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

SMART Unveils Faster, Safer T-Cell Therapy with New Detection Method

Singapore, 27 November 2023 – Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a…

Continue Reading SMART Unveils Faster, Safer T-Cell Therapy with New Detection Method

Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications

Agarwal P, Kabir FM, DeInnocentes P, Bird RC (2012) Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. Tumor Suppressor Genes 3(10):27882 Google Scholar  Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition…

Continue Reading Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here’s Why

Shares of CRISPR Therapeutics AG CRSP have rallied 41.9% in the past three months against the industry’s decline of 11.2%. CRISPR Therapeutics has co-developed a CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel [exa-cel]), in partnership with Vertex Pharmaceuticals VRTX, for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent…

Continue Reading CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here’s Why

GMP & RUO Grade iPSC Gene Editing & Differentiation Services | Lab Equipment

Use Applied StemCell’s (ASC) new GMP facility, comprised of five cleanrooms equipped with cutting-edge technology, to develop the next generation of iPSC-derived therapeutics. We have dedicated cleanrooms for induced pluripotent stem cells (iPSC), mesenchymal stromal cells (MSC), chimeric antigen receptor T-cells (CAR-T), T-cell receptor-engineered T-cells (TCR-T), natural killer (NK) cells,…

Continue Reading GMP & RUO Grade iPSC Gene Editing & Differentiation Services | Lab Equipment

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here’s Why – November 24, 2023

Shares of CRISPR Therapeutics AG (CRSP Quick QuoteCRSP – Free Report) have rallied 41.9% in the past three months against the industry’s decline of 11.2%. CRISPR Therapeutics has co-developed a CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel [exa-cel]), in partnership with Vertex Pharmaceuticals (VRTX Quick QuoteVRTX – Free Report) , for…

Continue Reading CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here’s Why – November 24, 2023

Nutrient found in beef and dairy improves immune response to cancer

Newswise — Trans-vaccenic acid (TVA), a long-chain fatty acid found in meat and dairy products from grazing animals such as cows and sheep, improves the ability of CD8+ T cells to infiltrate tumors and kill cancer cells, according to a new study by researchers from the University of Chicago. The…

Continue Reading Nutrient found in beef and dairy improves immune response to cancer

A Deep Dive into Trends, Players, and Growth

The gene therapy market has evolved into a juggernaut in the healthcare sector, displaying an extraordinary trajectory of growth. As of 2023, the gene therapy market has surged to a remarkable value of USD 6.36 billion, and the projection for the forthcoming years is nothing short of astonishing. Forecasts indicate…

Continue Reading A Deep Dive into Trends, Players, and Growth

a promising approach in cancer care

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current…

Continue Reading a promising approach in cancer care

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Development of mRNA-Directed Delivery – LNP Delivery System

During the COVID-19 pandemic, the success of mRNA vaccines has greatly propelled the development of mRNA therapeutics. mRNA is a negatively charged nucleic acid that serves as a template for protein synthesis in ribosomes. Despite its utility, the instability of mRNA necessitates appropriate carriers for in vivo delivery. Currently, lipid nanoparticles (LNPs) are…

Continue Reading Development of mRNA-Directed Delivery – LNP Delivery System

Breaking through immune suppression with CAR T cells

Since 2017, the United States Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapies for treating blood cancers (1). Behind the excitement around these therapies is the concern about patients’ short-lived responses to CAR T cell infusions, limiting their chances of long-term survival. CAR…

Continue Reading Breaking through immune suppression with CAR T cells

Approval Granted For Gene Therapy In Treating Sickle Cell Anaemia In The UK

Approval Granted For Gene Therapy In Treating Sickle Cell Anaemia In The UK Victoria Gray, the world’s first sickle cell anaemia patient to successfully recover from the condition with a gene-editing therapy. Gray, 38-year-old Gray is a resident of Forest City in Mississippi, US has been battling the genetic blood…

Continue Reading Approval Granted For Gene Therapy In Treating Sickle Cell Anaemia In The UK